Atul Sharma, MD
Ophthalmology · Atlanta, GANPI 1104829241
Payments from drug & device makers
Across 363 payments — averaging $530.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$121K
- US Retina LLC$29K
- Regeneron Healthcare Solutions, Inc.$20K
- AbbVie$7K
- Alcon$5K
- Alimera Sciences, Inc.$3K
- plus $7K from 23 others
What the payments were for
- Consulting fees$28,53537%
- Speaking & faculty fees$3,4024%
- Travel & lodging$6901%
- Food & beverage$15,21520%
- Ownership interest$28,86838%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $121,457 |
| US Retina LLC | 12 | $28,868 |
| Regeneron Healthcare Solutions, Inc. | 81 | $20,480 |
| AbbVie(2 entities) | 48 | $6,942 |
| Alcon | 33 | $4,765 |
| Alimera Sciences, Inc. | 21 | $2,795 |
| Genentech USA, Inc. | 68 | $2,738 |
| Notal Vision, Inc. | 8 | $1,002 |
| Apellis Pharmaceuticals, Inc. | 20 | $852 |
| ANI Pharmaceuticals, Inc. | 10 | $489 |
| Bausch & Lomb Americas Inc. | 5 | $349 |
| Novartis | 13 | $302 |
| Regeneron | 2 | $266 |
| Astellas Pharma US Inc | 9 | $241 |
| Coherus Oncology, Inc. | 9 | $194 |
| Carl Zeiss Meditec USA, Inc. | 1 | $133 |
| NEW World Medical,inc. | 1 | $133 |
| Dutch Ophthalmic, USA | 1 | $127 |
| Sandoz | 3 | $98 |
| Glaukos Corporation | 1 | $94 |
| Novartis Pharma AG | 1 | $92 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Biogen | 1 | $22 |
| Topcon Healthcare, Inc. | 1 | $20 |
| Eyepoint US, Inc. | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson Vision Care, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$11,974
- EYLEA HD$7,196
- OZURDEX$5,898
- PAVBLU$4,000
- Iluvien$2,616
- Constellation$2,243
- NGENUITY$1,276
- VABYSMO$760
- SUSVIMO$534
- Lucentis$401
- DAILIES$358
- XIPERE$288
- VISUDYNE$145
- Syfovre$141
- Clarus 700$133
- Ahmed Glaucoma Valve$133
- Kahook Dual Blade$133
- EVA Ophthalmic Surgical System$127
- PURIFIED CORTROPHIN GEL$120
How this compares
$192,567 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 73 | $2,910 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,606 |
| Atropine Sulfate | 69 | $2,218 |
| Travoprost | 22 | $1,957 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,195 |
| Brimonidine Tartrate | 13 | $1,111 |
| Ciprofloxacin Hcl | 47 | $476 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 48 | $369 |
| Latanoprost | 37 | $196 |
| Timolol Maleate | 17 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $6,942 | $2,60611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Atlanta
- Douglas DayAtlanta$1.1M
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Chris BergstromAtlanta$139K
- Anastasios CostaridesAtlanta$137K
- Evan SchoenbergAtlanta$130K
- Jiong YanAtlanta$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.